SCHEMBL5109138

SCHEMBL5109138

CNc1ncnc2c1ncn2-c1ccc(NC(=O)Nc2ccc(CN3CCCCC3)c(C(F)(F)F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.51
▸ ABL1 P00519 7/20 0.51
▸ RET P07949 4/20 0.51
▸ KDR P35968 4/20 0.51
▸ CDK8 P49336 4/20 0.51
▸ EGFR P00533 3/20 0.51
▸ FGFR4 P22455 3/20 0.51
▸ CDK2 P24941 2/20 0.51
▸ MKNK1 Q9BUB5 2/20 0.51
▸ MKNK2 Q9HBH9 2/20 0.51
▸ STK25 O00506 1/20 0.51
▸ CIT O14578 1/20 0.51
▸ MAP2K7 O14733 1/20 0.51
▸ IKBKB O14920 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ GAK O14976 1/20 0.51
▸ CHUK O15111 1/20 0.51
▸ MUSK O15146 1/20 0.51
▸ MAPK13 O15264 1/20 0.51
▸ MAP3K13 O43283 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5105942 0.99 SRC (0.52) SRCABL1RETKDRCDK8
SCHEMBL5106875 0.93 MKNK2 (0.60) SRCABL1RETKDRCDK8
SCHEMBL5119586 0.93 SRC (0.56) SRCABL1RETKDRCDK8
SCHEMBL5113819 0.92 SRC (0.50) SRCABL1RETKDRCDK8
SCHEMBL5108240 0.92 ABL1 (0.50) SRCABL1RETKDRCDK8
SCHEMBL5110191 0.92 ABL1 (0.46) SRCABL1RETKDRCDK8
SCHEMBL5105313 0.92 SRC (0.51) SRCABL1RETKDRCDK8
SCHEMBL5111191 0.92 CDK8 (0.49) SRCABL1RETKDRCDK8
SCHEMBL5106242 0.91 ABL1 (0.46) SRCABL1RETKDRCDK8
SCHEMBL5106248 0.91 SRC (0.51) SRCABL1RETKDRCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609656-B2 Heteroarylphenylurea derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-12-17 — — US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 — — US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 — — US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 — — US disclosed
EP-1724258-A1 HETEROARYLPHENYLUREA DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119466-A1 Heteroarylphenylurea Derivative CHRM1, CBR3, CHRM2 SRC 749/4885ABL1 128/4885RET 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback